AccelHeal

LECTRICAL STIMULATION WOUND THERAPY

Chronic wounds affect millions, reducing quality of life and placing a heavy cost burden on healthcare systems. Accel-Heal is transforming wound care with an innovative, wearable bioelectric device. This patented solution accelerates healing and relieves pain, addressing a critical need in a growing

\$20B wound care market.

SOLUTION

Micro-current electrical

Scalable and backed by

Clear and consistent

Accel-Heal's published

RCTs, and over 400

individual patients.

unique articles, including 2

Stimulation Therapy (EST)

MARKET

With the global wound care market projected to reach \$20 billion by 2033, Accel-Heal is targeting a SAM of \$10 billion and a SOM of \$1.9 billion.

FINANCIAL

£721K gross revenue in 2025

484K TREATMENT SALES IN 2034





STRATEGY

Reimbursed in its home UK market, with successful launches in France and UAE accelerating commercial adoption. Launches in progress in Italy, the Nordics, and Saudi Arabia and, with funding, entry into US, Japan, and other key markets planned.

CAPITAL RAISE

Accel-Heal is offering a compelling Series A investment opportunity at a £15M pre-money valuation, targeting £10M to drive rapid commercialization and scalable growth, positioning the company for significant market impact and value creation.

Led by industry veterans, including:

Andy Boyes, CEO (ex-Smith & Nephew) Andrew Wildman, CFO (ex-Ernst & Young)

EXIT STRATEGY

Accel-Heal presents an attractive acquisition opportunity, backed by scalable technology and minimal regulatory hurdles, positioning it for high growth and strategic value in the wound care market

Socially impactful and sustainable investment